Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CLLS

Cellectis ADR

May 29 • 02:10PM ET

3.60

-0.03 -0.83 %

Healthcare • Biotechnology • France • Micro • NASD

May 28, 11:40 AMBarclays initiates Cellectis coverage with Overweight rating on differentiated allogeneic CAR-T platform

Peers: ALLO CCCC CHRS REPL ALEC IMRX ZNTL ELDN LENZ GLSI

| Held by: IBB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.67	Insider Own	3.93%	Shs Outstand	100.60M	Perf Week	2.27%
Market Cap	260.39M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	0.00%	Shs Float	69.48M	Perf Month	-3.49%
Enterprise Value	183.33M	PEG	-	EPS next Q	-0.26	Inst Own	14.20%	Short Float	0.49%	Perf Quarter	-7.22%
Income	-67.60M	P/S	3.82	EPS this Y	-36.68%	Inst Trans	-0.47%	Short Ratio	8.29	Perf Half Y	-31.30%
Sales	68.15M	P/B	6.04	EPS next Y	19.52%	ROA	-20.69%	Short Interest	0.34M	Perf YTD	-25.62%
Book/sh	0.60	P/C	1.40	EPS next 5Y	-24.83%	ROE	-76.76%	52W High	5.48 -34.30%	Perf Year	150.00%
Cash/sh	2.57	P/FCF	-	EPS past 3/5Y	33.81% 18.84%	ROIC	-44.07%	52W Low	1.33 171.27%	Perf 3Y	96.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	56.25% -0.34%	Gross Margin	71.06%	Volatility	5.97% 5.76%	Perf 5Y	-77.03%
Dividend TTM	-	EV/Sales	2.69	EPS Y/Y TTM	-15.55%	Oper. Margin	-75.78%	ATR (14)	0.22	Perf 10Y	-88.47%
Dividend Ex-Date	-	Quick Ratio	1.52	Sales Y/Y TTM	43.21%	Profit Margin	-99.19%	RSI (14)	43.55	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.52	EPS Q/Q	2.04%	SMA20	-4.85%	Beta	2.87	Target Price	7.70
Payout	-	Debt/Eq	1.81	Sales Q/Q	-45.62%	SMA50	-3.24%	Rel Volume	1.29	Prev Close	3.63
Employees	229	LT Debt/Eq	1.56	Earnings	May 11 AMC	SMA200	-4.97%	Avg Volume	40.69K	Price	3.60
IPO	Mar 25, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	30.31% -31.63%	Trades		Volume	43,345	Change	-0.83%

Date	Action	Analyst	Rating Change	Price Target Change
May-28-26	Initiated	Barclays	Overweight	$9
Feb-17-26	Resumed	Jefferies	Buy	$7
Mar-17-23	Initiated	Bryan Garnier	Buy	$6
May-18-22	Upgrade	Robert W. Baird	Neutral → Outperform	$10
Jan-06-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$39 → $16
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$20
Nov-08-21	Downgrade	William Blair	Outperform → Mkt Perform
Oct-08-21	Downgrade	Robert W. Baird	Outperform → Neutral	$39 → $10
Apr-28-21	Downgrade	Guggenheim	Buy → Neutral
Mar-16-21	Upgrade	Robert W. Baird	Neutral → Outperform	$23 → $39
Aug-19-20	Upgrade	Citigroup	Neutral → Buy	$15 → $32
May-12-20	Initiated	Robert W. Baird	Outperform	$20
Mar-06-20	Downgrade	Goldman	Neutral → Sell	$15 → $11
Oct-30-19	Resumed	Guggenheim	Buy	$28
Aug-09-19	Initiated	BTIG Research	Buy	$37
May-24-19	Resumed	Citigroup	Neutral	$22
Mar-14-19	Initiated	William Blair	Outperform
Dec-19-18	Initiated	Goldman	Neutral
Jul-16-18	Initiated	Barclays	Overweight	$50
Mar-16-18	Initiated	Guggenheim	Neutral

Show Previous Ratings

May-28-26 11:26AM	Barclays initiates oncology-focused biotechs with positive outlook (Investing.com)
May-20-26 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 25, 2026 (GlobeNewswire)
May-12-26 09:30AM	Cellectis to Present Clinical Data on Lasme-cel and Eti-cel at EHA 2026 Annual Congress (GlobeNewswire)
May-11-26 04:30PM	Cellectis Reports Financial Results for the First Quarter 2026 (GlobeNewswire)
May-06-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.05%
04:30PM	Loading…
May-04-26 04:30PM	Cellectis to Report First Quarter Financial Results on May 11, 2026 (GlobeNewswire) -6.33%
Apr-27-26 04:30PM	Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting (GlobeNewswire)
Apr-13-26 04:30PM	Cema-Cel Pivotal Trial Interim Data Highlight Strength of Cellectis' Allogeneic CAR-T Platform (GlobeNewswire) +19.22%
Apr-07-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.65%
Mar-20-26 03:00PM	Cellectis SA (CLLS) Q4 2025 Earnings Call Highlights: Promising Clinical Progress and Strategic ... (GuruFocus.com)
Mar-19-26 07:21PM	Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)
09:17AM	What To Expect From Cellectis SA (XPAR:ALCLS) Q4 2025 Earnings (GuruFocus.com)
Mar-12-26 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 (GlobeNewswire) -12.37%
03:33AM	Poolbeg Pharma adds CAR-T therapy expert to scientific advisory board (Proactive)
Mar-04-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
04:30PM	Loading…
Feb-04-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-08-26 04:30PM	Cellectis Announces 2026 Strategy and Catalysts (GlobeNewswire)
Jan-05-26 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -5.42%
Dec-15-25 04:51PM	Cellectis Announces Arbitral Decision in Dispute with Servier (GlobeNewswire) -15.24%
Dec-08-25 01:30AM	ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL (GlobeNewswire)
Dec-03-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-19-25 06:18AM	Cellectis Publishes Nature Communications Article on a Non-Viral Gene Editing Process Enabling Efficient Gene Insertion in Hematopoietic Stem Cells (GlobeNewswire) +7.06%
Nov-07-25 04:30PM	Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +11.29%
11:30AM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-03-25 09:15AM	Cellectis to Present a Development Update for eti-cel at ASH 2025 (GlobeNewswire) -5.22%
Oct-31-25 04:30PM	Cellectis to Report Third Quarter Financial Results on November 7, 2025 (GlobeNewswire)
Oct-16-25 03:19PM	Cellectis' R&D Day Highlights Lasme-cel's Potential to Address Significant Unmet Need for Patients with r/r B-ALL (GlobeNewswire) +9.98%
07:00AM	Cellectis Hosts R&D Day Today Showcasing Pipeline Progress and Long-Term Value Drivers (GlobeNewswire)
Oct-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +8.22% +12.57%
02:40AM	Cellectis to Present Data on Non-Viral Gene Therapy and TALE Base Editors at the ESGCT Annual Congress (GlobeNewswire)
04:30PM	Loading…
Sep-03-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-04-25 04:30PM	Cellectis Reports Second Quarter 2025 Financial Results & Business Updates (GlobeNewswire) -16.23%
10:04AM	Earnings To Watch: Cellectis SA (CLLS) Reports Q2 2025 Result (GuruFocus.com)
Jul-28-25 04:30PM	Cellectis to Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire) +13.10%
Jul-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-26-25 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 (GlobeNewswire)
Jun-05-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-21-25 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025 (GlobeNewswire)
May-12-25 04:30PM	Cellectis Reports Financial Results for the First Quarter 2025 (GlobeNewswire) -6.62%
May-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-25 04:30PM	Cellectis to Report First Quarter Financial Results on May 12, 2025 (GlobeNewswire)
Apr-28-25 04:30PM	Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting (GlobeNewswire)
Apr-22-25 09:00AM	Cellectis Charts Course for 2025 With Boost From AstraZeneca Deal (MarketBeat)
Apr-21-25 05:02PM	Cellectis SA (CLLS) Q4 2024 Earnings Call Highlights: Strategic Collaborations and Financial ... (GuruFocus.com)
Apr-07-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.00%
Mar-13-25 06:07PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update (GlobeNewswire)
Mar-07-25 04:30PM	Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025 (GlobeNewswire)
Mar-06-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-24-25 01:30AM	Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 (GlobeNewswire)
Feb-04-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-28-25 08:00AM	Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer (GlobeNewswire)
Jan-08-25 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.10%
Jan-07-25 11:28AM	Do Options Traders Know Something About Cellectis (CLLS) Stock We Don't? (Zacks)
Dec-29-24 08:24AM	Analysts Predict 400% Upside Potential for This Penny Stock (GuruFocus.com)
Dec-10-24 04:30PM	Cellectis announces the drawdown of the third tranche of 5 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire)
Dec-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-06-24 04:38PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-05-24 04:30PM	Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting (GlobeNewswire)
Nov-04-24 04:30PM	Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 (GlobeNewswire)
07:14AM	What To Expect From Cellectis SA (CLLS) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 04:30PM	Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 (GlobeNewswire)
Oct-23-24 06:29AM	Cellectis Presents New Gene-Editing Breakthroughs (TipRanks) +9.44%
Oct-22-24 02:00AM	Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress (GlobeNewswire)
Oct-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Sep-03-24 04:30PM	Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety (GlobeNewswire) -5.83%
Aug-26-24 04:30PM	Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors (GlobeNewswire)
Aug-07-24 02:00AM	Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer (GlobeNewswire)
Aug-06-24 04:30PM	Cellectis Provides Financial Results for the Second Quarter 2024 (GlobeNewswire)
Aug-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Aug-02-24 09:53AM	Cellectis starts alemtuzumab revival with FDA orphan drug win in leukaemia (Pharmaceutical Technology)
Aug-01-24 04:30PM	FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment (GlobeNewswire)
Jul-25-24 04:30PM	FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment (GlobeNewswire) +12.20%
Jul-10-24 09:35AM	Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) (Zacks)
Jul-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-28-24 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 (GlobeNewswire)
Jun-20-24 04:30PM	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing (GlobeNewswire)
Jun-18-24 12:00PM	Cellectis (CLLS) Upgraded to Buy: Here's Why (Zacks) -5.84%
09:35AM	After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS) (Zacks)
Jun-12-24 04:30PM	Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications (GlobeNewswire)
Jun-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +6.23%
Jun-04-24 04:30PM	Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia (GlobeNewswire)
May-29-24 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 (GlobeNewswire)
May-28-24 08:52PM	CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	Cellectis Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-27-24 04:30PM	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 (GlobeNewswire)
May-16-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-06-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +12.04% -7.46%
04:22AM	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca (MT Newswires)
02:00AM	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca (GlobeNewswire)
May-03-24 06:10AM	Cellectis CFO Bing Wang Retires, Interim CFO Appointed (MT Newswires)
May-02-24 04:30PM	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer (GlobeNewswire) +17.90%
Apr-29-24 10:53PM	CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:46PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Apr-22-24 04:30PM	Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs (GlobeNewswire)
Apr-10-24 04:30PM	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs (GlobeNewswire)
Apr-08-24 04:30PM	Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting (GlobeNewswire)
Apr-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Mar-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.

Co-FounderDr. Andre Choulika Ph.D.

Co-FounderDr. David J. Sourdive Ph.D.

CFO & Chief Business OfficerMr. Arthur Stril

Principal Financial Officer & Principal Accounting OfficerValerie Cros

Chief Technological OfficerMr. Jean Charles Epinat Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLLS

Cellectis ADR

Upgrade your Finviz experience